On June 1, 2026, analyst firm Piper Sandler restated its Overweight rating for CVS Health (NYSE: CVS). This positive rating suggests the firm believes the healthcare stock will perform better than the average stock in its sector. At that time, the CVS Health stock price was $90.98. CVS Health is a major US healthcare company with retail pharmacies, a pharmacy benefits manager, and the Aetna insurance arm.
The company's focus on healthcare technology supports this positive outlook. As highlighted by Newsweek, CVS recently received the 2026 AI Impact Award for using artificial intelligence (AI) to improve medication safety in its pharmacies. This system helps interpret prescriptions and standardize instructions, freeing up pharmacists' time to focus on patient care across its national network, showcasing CVS innovation.
Aetna, a part of CVS, is also expanding its services. It announced Aetna Mental Health On Demand, a new service launching in 2027. This program gives members real-time access to mental health support. An early trial showed success, with clinicians connecting with members in an average of just 13 seconds, highlighting CVS's commitment to telehealth solutions.
CVS is also adapting to new market demands. On May 28, 2026, the company announced it will update its formularies to improve access to GLP-1 weight management drugs. Starting October 1, 2026, its pharmacy benefits manager, CVS Caremark, will once again cover Zepbound® to provide affordable options for these popular treatments, demonstrating CVS's responsiveness to pharmacy benefits management trends.
Shares of CVS are trading at $90.98, with a daily range between $90.57 and $93.55. Over the last 52 weeks, the CVS stock performance has shown trading from a low of $58.50 to a high of $98.43. The company currently has a market capitalization of approximately $116.08 billion based on a trading volume of 4.59 million shares.
